Projects by Topic

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years.

Adherence

Hematology

Hepatitis C

Expanding Hepatitis C Virus Care and Cure: National Experience Using a Clinical Pharmacist-Driven Model

The United States National Viral Hepatitis Action Plan calls for additional health care providers to expand hepatitis C virus (HCV) treatment capacity. This multi-site study evaluated the effectiveness of a clinical pharmacist-driven HCV delivery model in an open system. With an overall sustained virologic response (SVR) rate of 95% (per protocol), the clinical pharmacist-driven HCV treatment model was found to be effective and comparable to other real-world studies with specialist, non-specialist, and non-hepatology providers.

Download Manuscript Koren D, Zuckerman A, Teply R, Nabulsi N, Lee T, Martin M. Expanding hepatitis c virus care and cure: national experience using a clinical pharmacist-driven model. Open Forum Infect Dis, 2019 Jul; 6(17):ofz316. doi:10.1093/ofid/ofz316.

Presented: The Liver Meeting, San Francisco CA, November 2018
Download Poster : Koren D, Zuckerman A, Teply R, Nabulsi N, Lee T, Martin MT. Expanding hepatitis c virus care and cure: national experience using a clinical pharmacist-driven model. Poster presented to the American Association of the Study of Liver Diseases (AASLD)

MeRIT Project: Optimizing the Hepatitis C Cascade of Care in the Direct-Acting Antiviral Era

Dr. Zuckerman was selected for the ACCP Mentored Investigator Research Training Program (MeRIT). These poster presentations were project development presentations as part of the MeRIT program, which culminated in the ID Week poster and manuscript referenced.

Presented: American College of Clinical Pharmacy Annual Meeting, Phoenix AZ, October 2017
Download Poster:: Zuckerman A, Douglas A, Farris K, Chastain C. Merit project: optimizing the hepatitis c cascade of care in the direct-acting antiviral era. Presented: American College of Clinical Pharmacy Annual Meeting, Hollywood, FL. October, 2016
Download Poster:: Bagwell A, Farris K, Chastain C. MeRit project: optimizing the hepatitis c cascade of care in the direct-acting antiviral era.

Inflammatory Bowel Disease

Lipidology: PCSK9 Inhibitors

Impact of an Integrated Clinical and Specialty Pharmacy Service Model on Access to PCSK9 Inhibitor Therapy

This poster highlights the process and factors impacting the time to access PCSK9 inhibitors. These findings are expounded in the manuscript now published in the Journal of Clinical Lipidology.

Encore Poster Presented: National Association of Specialty Pharmacy Annual Meeting, Washington D.C., September 2018
Download PosterReynolds V, Peter M, Jolly J, Chinn M, Nwosu S, Choi L, Zuckerman A. Impact of an Integrated Clinical and Specialty Pharmacy Service Model on Access to PCSK9 Inhibitor Therapy

Presented: American Society of Health Systems Pharmacists Midyear Clinical Meeting and Exhibition, Orlando, FL, December 2017
Download PosterChinn M, Reynolds V, Jolly J, Zuckerman A, Kelley T. Impact of an Integrated Clinical and Specialty Pharmacy Service Model on Access to PCSK9 Inhibitor Therapy

Multiple Sclerosis

Neurology / Movement Disorders

Impact of Specialty Pharmacist Integration on Time to Medication Access for Pimavanserin

Patient access to pimavanserin treatment, an antipsychotic agent used to treat Parkinson’s disease-related psychosis, is limited by insurance approval and navigating a limited distribution network. Once initiated, safety and efficacy monitoring is needed to ensure adherence and clinical benefit. In this study, we found the time to access pimavanserin reduced by 21 days on average after pharmacist integration. Similarly, the rate of third party approval increased by 16% and treatment initiation increased by 18%.

Encore poster to be presented to the National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo, Washington, DC. September, 2019.
Download posterLivezey S, McCormick R, Shah N, Choi L, DeClercq J, Zuckerman A. Impact of specialty pharmacist integration on time to medication access for pimavanserin.

Presented: College of Psychiatric and Neurologic Pharmacists Annual Meeting, Salt Lake City, UT, April 2019
Download posterLivezey S, McCormick R, Shah N, Choi L, DeClercq J, Zuckerman A. Impact of specialty pharmacist integration on time to medication access for pimavanserin.

Oncology

Osteoporosis

Lapses and Discontinuations in Denosumab Therapy: Associations with Fracture Incidence

The purpose of the study was to assess rates of treatment lapses and discontinuations and associations with fracture incidence in adult patients treated with denosumab, a clinic-administered osteoporosis treatment given every six months.

Poster presented to the International Society for Clinical Densitometry Annual Meeting, Kuala Lumpur, Malaysia. March, 2019.

Pulmonary Arterial Hypertension

Specialty Pharmacy Practice

Transplant

Development of a Pharmacy Collaborative Practice Agreement to Improve Efficiency and Management of Prescribing in a Renal Transplant Clinic

Post-transplant patients require complex medication regimens to ensure the survival of the transplanted organ and patient overall well-being. These regimens are frequently adjusted, initiated, or discontinued within soon after transplant. Pharmacist expertise can be utilized to optimize post-transplant medication use. This study describes the creation and corresponding outcomes of a Collaborative Pharmacy Practice Agreements (CPPA) between pharmacists and physicians within a renal transplant clinic.

Presented: National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo, Washington, DC., September 2019. *Top poster award winer*
Download poster Chelewski R, Johnson K, Zuckerman A, DeClercq J, Choi L, Peter M, Langone A. Development of a collaborative pharmacy practice agreement to improve efficiency and management of prescribing in a renal transplant clinic.

Presented: American Transplant Congress Annual Meeting, Boston, MA, June 2019
Podium Presentation R. Chelewski, K. Johnson, A. Zuckerman, Declerq J, Choi L, Peter M, A. Langone. Development of a Pharmacy Collaborative Practice Agreement to Improve Efficiency and Management of Prescribing in a Renal Transplant Clinic.

Presented: Academy of Managed Care and Specialty Pharmacy Annual Meeting, San Diego, CA. March, 2019. *Gold ribbon abstract winner*
Download poster R. Chelewski R, Johnson K, Zuckerman A, Peter M, DeClercq J, Choi L, Langone A. Development of a pharmacy collaborative practice agreement to improve efficiency and management of prescribing in a renal transplant clinic.